President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

The pharmaceutical industry faces an innovation crisis with declining R&D productivity, rising costs, and regulatory challenges impacting drug development.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today the pricing of $400.0 million aggregate ...

The global peptide and anticoagulant drugs market is witnessing significant growth, driven by factors such as the rising prevalence of cardiovascular diseases, technological advancements, and the ...

The biosimilars market represents a transformative segment within the global pharmaceutical industry, offering highly similar ...

The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplan ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Archer Daniels Midland logged lower profit and revenue in the second quarter, hurt by what Chief Executive Juan Luciano called a challenging environment. Yum Brands logged higher profit and sales in ...

Pfizer Inc (NYSE: PFE) saw its shares rise by more than 4% after the company reported strong second-quarter results that ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president sent a letter pushing drug companies to slash prices.

President Donald Trump sent letters to 17 pharmaceutical companies Thursday, urging them to match drug prices to the lowest price offered in other developed countries within ...